{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T19:36:20Z","timestamp":1772652980609,"version":"3.50.1"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polymyxin B remains a key treatment option for infections caused by multidrug-resistant gram-negative bacilli, particularly in critically ill patients. However, its optimal dosing strategy recommendation remains uncertain, especially in those undergoing renal replacement therapy. This study aimed to compare the clinical and microbiological outcomes of low, usual and high dose polymyxin B in a real-world ICU population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This 5-year retrospective cohort study included critically ill adult patients with gram-negative sepsis who received polymyxin B. Patients were categorized into low-, usual- and high-dose groups based on loading and total daily maintenance dose. Pairwise propensity score matching was performed to adjust for baseline differences. Primary outcome was 28-day all-cause mortality. Secondary outcomes included microbiological clearance, ventilator-free days, ICU-free days, and vasopressor-free days. Subgroup and sensitivity analyses were conducted, including within patients requiring dialysis. All the statistical analysis was performed using R software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 674 patients were included. After matching, usual-dose polymyxin B (61%) was associated with significantly higher 28-day mortality compared to the low-dose group (48.04%) (HR\u2009=\u20091.47;95% CI:[1.11\u20131.95];p\u2009=\u20090.007). Vasopressor, ventilator and ICU-free days were also significantly higher in the low-dose group were compared to the other groups. No significant survival advantage was observed with high-dose regimens. Among dialysis-dependent patients (n\u2009=\u2009254), mortality did not differ significantly across dosing groups, though microbiological clearance was better with low dosing. Sensitivity and subgroup analysis also supported the results to be robust.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low dose polymyxin B regimens were associated with lower mortality and comparable clinical outcomes compared to higher doses and may be feasible in critically ill patients with renal impairment. However, these findings should be interpreted cautiously given the observational design and residual confounding, warranting confirmation in future randomized trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0342835","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:26:46Z","timestamp":1772648806000},"page":"e0342835","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes with lower versus conventional dose polymyxin B regimens in dialysis dependent and non-dialysis patients with gram-negative sepsis: A real-world propensity-score matched cohort study"],"prefix":"10.1371","volume":"21","author":[{"given":"Asha K.","family":"Rajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5255-6148","authenticated-orcid":true,"given":"Vishal","family":"Shanbhag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayanarayana","family":"Kunhikatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravindra Prabhu","family":"Attur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beven","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun Kumar","family":"S. G","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souvik","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1257-969X","authenticated-orcid":true,"given":"Girish","family":"Thunga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"2","key":"pone.0342835.ref001","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.idc.2016.02.004","article-title":"Multidrug-resistant bacteria in the community: Trends and lessons learned","volume":"30","author":"D van Duin","year":"2016","journal-title":"Infect Dis Clin North Am"},{"issue":"8","key":"pone.0342835.ref002","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3390\/microorganisms11081912","article-title":"The challenge of overcoming antibiotic resistance in carbapenem-resistant gram-negative bacteria: \u201cAttack on Titan\u201d","volume":"11","author":"G Mancuso","year":"2023","journal-title":"Microorganisms"},{"issue":"12","key":"pone.0342835.ref003","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1586\/14787210.2015.1093933","article-title":"Polymyxin B versus colistin: An update","volume":"13","author":"Y Cai","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"12","key":"pone.0342835.ref004","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/antibiotics11121711","article-title":"Next-generation polymyxin class of antibiotics: A ray of hope illuminating a dark road","volume":"11","author":"AT Aslan","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"pone.0342835.ref005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13054-023-04448-z","article-title":"Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study","volume":"27","author":"T Tang","year":"2023","journal-title":"Crit Care"},{"issue":"1","key":"pone.0342835.ref006","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/antibiotics8010024","article-title":"Polymyxin acute kidney injury: Dosing and Other strategies to reduce toxicity","volume":"8","author":"RL Nation","year":"2019","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"pone.0342835.ref007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"BT Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"pone.0342835.ref008","doi-asserted-by":"crossref","first-page":"955633","DOI":"10.3389\/fphar.2022.955633","article-title":"Polymyxin B in patients with renal impairment: Is it necessary to adjust dose?","volume":"13","author":"R Nie","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0342835.ref009","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jgar.2025.05.003","article-title":"Real-world performance in therapeutic target attainment of various recommended polymyxin B dose regimens: Secondary data analysis of a prospective multicenter cohort","volume":"43","author":"J Liu","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"pone.0342835.ref010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13054-023-04522-6","article-title":"Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: The PMB-CROS randomized clinical trial","volume":"27","author":"S Liu","year":"2023","journal-title":"Crit Care"},{"key":"pone.0342835.ref011","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2147\/IDR.S357746","article-title":"Polymyxin B-Based regimens for patients infected with carbapenem-resistant gram-negative bacteria: Clinical and microbiological efficacy, mortality, and safety","volume":"15","author":"J Qu","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"1","key":"pone.0342835.ref012","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s12967-021-03111-x","article-title":"Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: A real-world multicenter study","volume":"19","author":"X Zhang","year":"2021","journal-title":"J Transl Med"},{"key":"pone.0342835.ref013","volume-title":"Septic Shock","author":"S Mahapatra","year":"2024"},{"issue":"8","key":"pone.0342835.ref014","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"M Singer","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"pone.0342835.ref015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"A-P Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"pone.0342835.ref016","volume-title":"Acute Kidney Injury","author":"A Goyal","year":"2025"},{"key":"pone.0342835.ref017","volume-title":"Acute Respiratory Distress Syndrome","author":"M Diamond","year":"2025"},{"key":"pone.0342835.ref018","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/B978-0-7020-5140-1.00036-5","article-title":"Biochemical aspects of neurological disease","volume-title":"Clinical Biochemistry: Metabolic and Clinical Aspects","author":"P Hart","year":"2014"},{"issue":"7","key":"pone.0342835.ref019","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"PC Austin","year":"2014","journal-title":"Stat Med"},{"issue":"5","key":"pone.0342835.ref020","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40262-025-01488-2","article-title":"A systematic review of pharmacokinetic studies of colistin and polymyxin B in adult populations","volume":"64","author":"PJ Zamri","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"pone.0342835.ref021","doi-asserted-by":"crossref","first-page":"1122310","DOI":"10.3389\/fphar.2023.1122310","article-title":"Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients","volume":"14","author":"D Liang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"9","key":"pone.0342835.ref022","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/jcph.2261","article-title":"Population pharmacokinetic modeling using polymyxin B free plasma concentrations from published reports and evaluation of dosage regimens based on monte carlo simulation in critically Ill Patients","volume":"63","author":"Y Zheng","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"pone.0342835.ref023","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/jac\/dku561","article-title":"Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: A multicentre prospective cohort study","volume":"70","author":"MH Rigatto","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"pone.0342835.ref024","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/antibiotics9080451","article-title":"Clinical experience with high-dose polymyxin B against carbapenem-resistant gram-negative bacterial infections-A cohort study","volume":"9","author":"Y Cai","year":"2020","journal-title":"Antibiotics (Basel)"},{"issue":"11","key":"pone.0342835.ref025","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1128\/AAC.00844-15","article-title":"Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods","volume":"59","author":"BC Nelson","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:26:54Z","timestamp":1772648814000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342835"}},"subtitle":[],"editor":[{"given":"Saswat","family":"Mohapatra","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342835","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}